Clinical course, prognosis, and causes of death in mixed connective tissue disease

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1134-1142

  Hajas, Agota ^a   Szodoray, Peter ^b   Nakken, Britt ^b   Gaal, Janos ^c   Zold, Eva ^a   Laczik, Renata ^a   Demeter, Nora ^d   Nagy, Gabor ^a   Szekanecz, Zoltan ^a   Zeher, Margit ^a   Szegedi, Gyula ^a   Bodolay, Edit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF OSLO   (Norway)

^c Kenezy Hospital   (Hungary)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Antiphospholipid Syndrome; Cardiovascular Events; Clinical Course; Mixed Connective Tissue Disease; Prognosis; Survival

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; ENDOTHELIAL CELL ANTIBODY;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; DISEASE COURSE; ESOPHAGEAL HYPOMOTILITY; ESOPHAGUS DISEASE; FEMALE; HUMAN; HUNGARY; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR EVENTS; CLINICAL COURSE; MIXED CONNECTIVE TISSUE DISEASE; PROGNOSIS; SURVIVAL;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; PROGNOSIS; SURVIVAL RATE;

EID: 84879955753     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121272     Document Type: Article

References (55)

1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease-An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.
2. Sharp GC, Irvin WS, LaRoque RL, Velez C, Daly V, Kaiser AD, et al. Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. J Clin Invest 1971;50:350-9.
3. Hoffmann RW, Cassidy JT, Takeda Y, Smith-Jones EL, Wang GS, Sharp GC. U1-70 kD autoantibody positive connective tissue disease in children: A longitudinal clinical and serological analysis. Arthritis Rheum 1993;36:1599-602.
4. Kasukawa R. Mixed connective tissue disease. Intern Med 1999;38:386-93.
5. O'Connell DJ, Bennett RM. Mixed connective tissue disease: Clinical and radiological aspects of 20 cases. Br J Radiol 1970;50:620-5.
6. Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M, et al. Anticyclic citrullinated peptide antibodies in patients in mixed connective tissue disease. Mod Rheumatol 2004;14:367-75.
7. Maldonado ME, Perez M, Pignac-Kobinger J, Marx ET, Tozman EM, Greidinger EL, et al. Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population. J Rheumatol 2008;35:1-9.
8. Prakash UB, Luthra HS, Divertie MB. Intrathoracic manifestations in mixed connective tissue disease. Mayo Clin Proc 1985;60:813-21.
9. Prakash UB. Lungs in mixed connective tissue disease. J Thorac Imaging 1992;7:55-61.
10. Hoffman RW, Maldonado ME. Immune pathogenesis of mixed connective tissue disease: A short analytical review. Clin Immunol 2008;128:8-17.
11. Vianna MA, Borges CT, Borba EF, Caleiro MT, BonfáE, Marie SK. Myositis in mixed connective tissue disease: A unique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis. Arq Neuropsiquiatr 2004;62:923-34.
12. Bodolay E, Szekanecz Z, Devenyi K, Galuska L, Csip I, Vegh J, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology 2005;44:656-61.
13. Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: An overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol 2012;26:61-72.
14. Gaá J, Varga J, Szabados L, Garai I, Galuska L, Suráyi P, et al. High prevalence of oesophageal involvement in patients with undifferentiated connective tissue disease using radionuclide oesophageal transit scintigraphy. Nucl Med Commun 2005;26:1113-7.
15. Gunnarsson R, Molberg O, Gilboe I, Gran JT. The prevalence and incidence of mixed connective tissue disease: A national multicentre survey of Norwegian patients. PAHNOR1 Study Group. Ann Rheum Dis 2011;70:1047-51.
16. Szodoray P, Hajas A, Kardos L, Dezso B, Soos G, Zold E, et al. Distinct phenotypes in mixed connective tissue disease: Subgroups and survival. Lupus 2012;21:1412-22.
17. Miyawaki S, Onodera H. Clinical course and prognosis of patients with mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division); 1987:331-6.
18. Suzuki M, Hamada M, Sekiya M, Shigematsu Y, Go S, Hiwada K. Fatal pulmonary hypertension in a patient with mixed connective tissue disease: Report of an autopsy case. Intern Med 1992;31:74-7.
19. Ueda N, Mimura K, Sugiyama T, Kado T. Mixed connective tissue disease with fatal pulmonary hypertension and a review of literature. Virchows Arch (Pathol Anat) 1984;404:335-40.
20. Wiener-Kronish JP, Solinger AM, Warnock ML, Churg A, Ordonez N, Golden JA. Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis 1981;124:499-503.
21. Manthorpe R, Elling H, van der Meulen JT, Sorensen S. Two fatal cases of mixed connective tissue disease. Scand J Rheumatol 1980;9:7-10.
22. Greidinger EL. Delayed development of pulmonary arterial hypertension in mixed connective tissue disease. J Postgrad Med 2005;51:108.
23. Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin N Am 2005;31:451-64.
24. Venables PJ. Mixed connective tissue disease. Lupus 2006;15:132-7.
25. Jones MB, Osterholm RK, Wilson RB, Martin FH, Commers JS, Bachmayer JD. Fatal pulmonary hypertension and resolving immune-complex glomerulonephritis in mixed connective tissue disease. Am J Med 1978;65:855-63.
26. Alarcon-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division); 1987:33-40.
27. Bodolay E, Csipo I, Gái I, Sipka S, Gyimesi E, Szekanecz Z, et al. Anti-endothelial cell antibodies in mixed connective tissue disease: Frequency and association with clinical symptoms. Clin Exp Rheumatol 2004;22:409-15.
28. Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol 2008;22:1093-108.
29. de Holanda Mafaldo Dióenes A, BonfáE, Fuller R, Correia Caleiro MT. Capillaroscopy is a dynamic process in mixed connective tissue disease. Lupus 2007;16:254-8.
30. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alperts CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
31. Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G, et al. 'Criteria' aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011;20:182-90.
32. Asherson RA, Cervera R. "Primary", "secondary" and other variants of the antiphospholipid syndrome. Lupus 1994;3:29-38.
33. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
34. Bodolay E, Seres I, Szodoray P, Csip I, Jakab Z, Vegh J, et al. The evaluation of paraoxonase (PON) activity in patients with mixed connective tissue disease. J Rheumatol 2008;35:237-43.
35. Soltéz P, Bereczki D, Szodoray P, Magyar TM, Der H, Csip I, et al. Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. Arthritis Res Ther 2010;12:R78.
36. Soltéz P, Kerekes G, Der H, Szucs G, SzantoS, Kiss E, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment. Autoimmun Rev 2011;10:416-25.
37. Hajas A, Sandor J, Csathy L, Csip I, Barath S, Paragh G, et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 2011;6:317-24.
38. Vegh J, Szodoray P, Kappelmayer J, Csip I, Udvardy M, Lakos G, et al. Clinical and immunoserological characteristics of mixed connective tissue disease (MCTD) associated with pulmonary arterial hypertension (PAH). Scand J Immunol 2006;64:69-76.
39. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings. Arthritis Rheum 1999;42:899-909.
40. Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA, Maltby JD, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine 1984;63:92-107.
41. Bodolay E, Gaá J, Vegh J, Soltéz P, Szodoray P, Lakos G, et al. Evaluation of survival in mixed connective tissue disease (MCTD) [Hungarian]. Orv Hetil 2002;143:2543-8.
42. Grant KD, Adams LE, Hess EV. Mixed connective tissue disease-a subset with sequential clinical and laboratory features. J Rheumatol 1981;8:587-98.
43. Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: A subsequent evaluation of the original 25 patients. Medicine 1980;59:239-48.
44. Hasegawa EM, Caleiro MT, Fuller R, Carvalho JF. The frequency of anti-beta 2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus 2009;18:618-21.
45. Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M, et al. Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 1999;26:2357-62.
46. Vegh J, Soos G, Csipo I, Demeter N, Ben T, Dezso B, et al. Pulmonary arterial hypertension in mixed connective tissue disease: Successful treatment with iloprost. Rheumatol Int 2006;26:264-9.
47. Jais X, Launay D, Yaici A, Pavec JL, Tcheakian C, Sitbon O, et al. Immunosuppressive therapy in lupus and mixed connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2008;58:521-31.
48. Yamaguchi T, Ohshima S, Tanaka T, Tsukada S, Matsushita M, Kohmo S, et al. Renal crisis due to intimal hyperplasia in a patient with mixed connective tissue disease (MCTD) accompanied by pulmonary hypertension. Intern Med 2001;40:1250-3.
49. Del Papa N, Sheng YH, Raschi E, Kandiah DA, Tincani A, Khamashta MA, et al. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol 1998;160:5572-8.
50. Paice EW, Snaith ML. Thrombotic thrombocytopenic purpura occurring in a patient with mixed connective tissue disease. Rheumatol Int 1984;4:141-2.
51. Kato A, Suzuki Y, Fujigaki Y, Yamamoto T, Yonemura K, Miyajima H, et al. Fatal complication of thrombotic microangiopathy in a patient with mixed connective tissue disease. Rheumatol Int 2002;22:122-5.
52. Lin YC, Wu CC, Ou TT, Yen JH, Liu HW, Tsai WC. Malignant thymoma associated with mixed connective tissue disease: A case report. Clin Rheumatol 2006;25:262-4.
53. Fujiwara H, Nakamura D, Kukita T, Hamada H, Ozaki A, Matsushita K, et al. Immunosuppressive treatment for mixed connective tissue disease may facilitate the development of adult T cell leukemia/lymphoma in a HTLVI carrier. Intern Med 2006;45:297-301.
54. Szekanecz E, Szamosi S, Horvath A, Nemeth A, Juhasz B, Szanto J., et al. Malignancies associated with systemic sclerosis. Autoimmun Rev 2012;11:852-5.
55. Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010;9:195-9.